DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

Core Viewpoint - DOMA Perpetual believes that Pacira BioSciences' stock is undervalued, presenting an opportunity for the company to execute its largest buyback in history [1][4]. Group 1: Capital Allocation and Shareholder Value - DOMA Perpetual views the new capital allocation announcement as a strong commitment from Pacira's Board to enhance shareholder value [2]. - The combination of a $300 million share repurchase program and a focus on increasing pre-tax net income margins is expected to strengthen shareholder returns [3]. - The management is now tasked with effectively executing these initiatives to realize their potential [3]. Group 2: Growth and Financial Position - DOMA Perpetual is encouraged by Pacira's steps towards long-term value creation, indicating a period of rapid growth for the company [4]. - The new capital allocation priorities reflect Pacira's considerable momentum in scaling earnings and free cash flow, allowing for meaningful capital returns to shareholders while still investing in growth [4]. - The stock is considered undervalued relative to its historical average and the anticipated multi-year growth cycle ahead [4].